Simões Corrêa Galendi J, Leite RGOF, Banzato LR, Nunes-Nogueira VDS. Effectiveness of strategies for nutritional therapy for patients with type 2 diabetes and/or hypertension in primary care: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(7):4243.

Article  PubMed  PubMed Central  Google Scholar 

Guilbert E, Perry R, Whitmarsh A, Sauchelli S. Short-term effectiveness of nutrition therapy to treat type 2 diabetes in low-income and middle-income countries: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022;12(3): e056108.

Article  PubMed  PubMed Central  Google Scholar 

Schwingshackl L, Chaimani A, Hoffmann G, Schwedhelm C, Boeing H. A network meta-analysis on the comparative efficacy of different dietary approaches on glycemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018;33(2):157–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emadian A, Andrews RC, England CY, Wallace V, Thompson JL. The effect of macronutrients on glycemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br J Nutr. 2015;114(10):1656–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hurst Y, Fukuda H. Effects of changes in eating speed on obesity in patients with diabetes: a secondary analysis of longitudinal health check-up data. BMJ Open. 2018;8(1): e019589.

Article  PubMed  PubMed Central  Google Scholar 

Saito Y, Kajiyama S, Nitta A, Miyawaki T, Matsumoto S, Ozasa N, Kajiyama S, Hashimoto Y, Fukui M, Imai S. Eating fast has a significant impact on glycemic excursion in healthy women: randomized controlled cross-over trial. Nutrients. 2020;12(9):2767.

Article  PubMed  PubMed Central  Google Scholar 

Jakubowicz D, Wainstein J, Ahren B, Landau Z, Bar-Dayan Y, Froy O. Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial. Diabetes Care. 2015;38(10):1820–6.

Article  CAS  PubMed  Google Scholar 

Jakubowicz D, Wainstein J, Ahrén B, Bar-Dayan Y, Landau Z, Rabinovitz HR, Froy O. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. Diabetologia. 2015;58(5):912–9.

Article  CAS  PubMed  Google Scholar 

Ogata H, Hatamoto Y, Goto Y, Tajiri E, Yoshimura E, Kiyono K, Uehara Y, Kawanaka K, Omi N, Tanaka H. Association between breakfast skipping and postprandial hyperglycaemia after lunch in healthy young individuals. Br J Nutr. 2019;122(4):431–40.

Article  CAS  PubMed  Google Scholar 

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;11:107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masaki T, Ozeki Y, Yoshida Y, Okamoto M, Miyamoto S, Gotoh K, Shibata H. Glucagon-like peptide-1 receptor agonist semaglutide improves eating behavior and glycemic control in japanese obese type 2 diabetic patients. Metabolites. 2022;12(2):147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, Briere DA, Benson C, Nauck MA, Haupt A. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998–1004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki T, Sato T, Tanaka M, Endo K, Nakata K, Ogawa T, Hosaka I, Akiyama Y, Umetsu A, Furuhashi M. Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus. J Diabetes Complications. 2024;38(7): 108779.

Article  CAS  PubMed  Google Scholar 

Zabel R, Ash S, King N, Juffs P, Bauer J. Relationships between appetite and quality of life in hemodialysis patients. Appetite. 2012;59(1):194–9.

Article  PubMed  Google Scholar 

Acar Tek N, Karaçil-Ermumcu M. Determinants of health related quality of life in home dwelling elderly population: appetite and nutritional status. J Nutr Health Aging. 2018;22(8):996–1002.

Article  CAS  PubMed  Google Scholar 

Araki A, Izumo Y, Inoue J, Hattori A, Nakamura T, Takahashi R, Takanashi K, Teshima T, Yatomi N, Shimizu Y, Ito H. Burden of dietary therapy on elderly patients with diabetes. Mellitus Jpn J Geriat. 1995;32:804–9.

Article  CAS  Google Scholar 

Sato E, Ochiai R, Shibayama T, Nishigaki M, Abe Y, Sawa T, Suzukamo Y, Kazuma K. Reliability and validity of revised and short form versions of diabetes diet-related quality of life scale. Diabetol Int. 2016;8(2):181–92.

Article  PubMed  PubMed Central  Google Scholar 

Ogawa W, Hirota Y, Miyazaki S, Nakamura T, Ogawa Y, Shimomura I, Yamauchi T, Yokote K. Creation Committee for Guidelines for the Management of Obesity Disease 2022 by Japan Society for the Study of Obesity (JASSO). Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2024;71(3):223–31.

Article  PubMed  Google Scholar 

Matza LS, Stewart KD, Landó LF, Patel H, Boye KS. Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes. Patient. 2022;15(3):367–77.

Article  PubMed  PubMed Central  Google Scholar 

Ishii H, Oura T, Takeuchi M. Treatment satisfaction and quality of life with tirzepatide versus dulaglutide among japanese patients with type 2 diabetes: exploratory evaluation of the SURPASS. J-mono Trial Diabetes Ther. 2023;14(12):2173–83.

Article  CAS  PubMed  Google Scholar 

Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev. 2002;18(Suppl 3):S64–9.

Article  PubMed  Google Scholar 

Bettadapura S, Dowling K, Jablon K, Al-Humadi AW, le Roux CW. Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. Int J Obes Lond. 2024. https://doi.org/10.1038/s41366-024-01500-y.

Article  PubMed  PubMed Central  Google Scholar 

Kadouh H, Chedid V, Halawi H, Burton DD, Clark MM, Khemani D, et al. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020;105:1552–63.

Article  PubMed  Google Scholar 

Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geisler CE, Antonellis MP, Trumbauer W, Martin JA, Coskun T, Samms RJ, Hayes MR. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab. 2023;25(1):56–67.

Article  CAS  PubMed  Google Scholar 

Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diabetes Obes Metab. 2023;25(2):398–406.

Article  CAS